RHHBF - Spyre gains as TD Cowen starts at Outperform on anti-TL1A potential
2023-11-29 13:38:43 ET
More on Aeglea BioTherapeutics
- Aeglea Biotherapeutics announces name change to Spyre Therapeutics
- Aeglea BioTherapeutics announces 1-for-25 reverse stock split
- Seeking Alpha’s Quant Rating on Aeglea BioTherapeutics
- Historical earnings data for Aeglea BioTherapeutics
- Financial information for Aeglea BioTherapeutics
For further details see:
Spyre gains as TD Cowen starts at Outperform on anti-TL1A potential